

Dr. Lal PathLabs Limited records revenue growth of 12.1% to Rs 327.9 Cr in Q3 FY 2019-20

New Delhi, India, Feb 3, 2020 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2019

Consolidated Performance Highlights: Q3 FY 2019-20 vs Q3 FY 2018-19

**Revenue growth: 12.1% at Rs 327.9 Cr,
Normalised EBITDA ex Ind AS 116 at Rs 80.1 Cr,
Normalised EBITDA margins ex Ind AS 116 at 24.4%,
PBT at Rs 73.4 Cr, and PAT Rs 54.9 Cr with margin at 16.7%**

- Operating Revenue increased by 12.1% in Q3 FY20 to Rs. 327.9 Cr vs Rs 292.5 Cr in the previous year same quarter. Underlying patient volume growth is 11.3% during the quarter
- Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116) for Q3FY20 grew 13.5 % to Rs. 80.1 Cr from Rs 70.6 Cr in the same quarter last year
- Normalised EBITDA Margin ex Ind AS 116 at 24.4% for Q3 FY20
- PBT is at Rs 73.4 Cr in Q3 FY20 vs Rs 67.9 Cr. in Q3 last year, a growth of 8.1%
- Profit after Tax in Q3 FY20 at Rs. 54.9 Cr as compared to Rs 46.1 Cr in Q3 last year, a growth of 19.1%
- Company’s wholly owned subsidiary Pathlabs Unifiers Private Ltd. has signed a binding term sheet to acquire the business of M/S Shree Computerised Pathology Laboratory and M/S Modern Diagnostics & Modern Lab for further strengthening the company’s presence in the state of Maharashtra

Financial Overview (Consolidated) in Rs Cr

Particulars	Q3 FY20 (With IND- AS 116)	Q3 FY20 (W/O IND- AS 116)	Q3 FY19 (W/O IND- AS 116)	Gr % (With IND-AS 116)	Gr % (W/O IND-AS 116)	YTD Q3 FY20 (With IND- AS 116)	YTD Q3 FY20 (W/O IND- AS 116)	YTD Q3 FY19 (W/O IND- AS 116)	Gr % (With IND-AS 116)	Gr % (W/O IND-AS 116)
Revenue	327.9	327.9	292.5	12.1%	12.1%	1028.7	1028.7	902.3	14.0%	14.0%
Expenditure	245.6	254.4	226.9			742.4	768.2	674.9		
EBITDA	82.3	73.5	65.6	25.5%	12.0%	286.3	260.5	227.4	25.9%	14.6%
Adj for Stock based compensation & CSR cost	6.6	6.6	5.0			15.1	15.1	13.0		
Normalised EBITDA	88.9	80.1	70.6	25.9%	13.5%	301.4	275.6	240.4	25.4%	14.6%
Normalised Margins	27.1%	24.4%	24.1%			29.3%	26.8%	26.6%		
Other income	13.8	13.8	12.2			43.0	43.0	32.5		
PBT	73.4	75.9	67.9	8.1%	11.8%	265.1	272.6	231.4	14.6%	17.8%
Margins	22.4%	23.1%	23.2%			25.8%	26.5%	25.6%		
PAT	54.9	56.7	46.1	19.1%	23.0%	195.0	200.3	153.1	27.4%	30.8%
Margins	16.7%	17.3%	15.8%			19.0%	19.5%	17.0%		
EPS (Basic)	6.56		5.56	18.0%		23.48		18.48	27.1%	
EPS (Diluted)	6.55		5.55	18.0%		23.42		18.45	26.9%	



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2019 the company has 200 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 2,569 Patient Service Centers (PSCs) and 6,426 Pick-up Points (PUPs). It's customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Mittali Bharti
Adfactors PR

+91 9871154558
mittali.bharti@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.